Navigation Links
New Drug More Effective than Tamoxifen in Preventing Breast Cancer Relapse

New research appearing in the December 29 issue of the New England Journal of Medicine says that a new drug called as Femara is better than tamoxifen fro preventing the chances // of a relapse of breast cancer. Femara is a drug manufactured by Novartis AG and is chemically letrozole.

This belongs to a class of drugs called as the aromatase inhibitors of which Arimidex is also a part. In the current study, which was co-ordinated by the Senology Center of Eastern Switzerland in Kantonsspital, 8,000 women were assessed after taking either tamoxifen or Femara. It was found that Femara reduced the chances of breast cancer relapse by 29 percent over what tamoxifen achieved. In addition to this, Femara also conferred a 27 percent less chance of metastasis of the cancer to other parts of the body. Tamoxifen is regarded as the "gold standard" in treatment of breast cancer, but this new class of drugs is demonstrating better results in hormone-sensitive breast cancer. This is especially true in post-menopausal women, who are more prone to develop estrogen-related breast cancer. Femara works by reducing the levels of this hormone, which is essential to trigger the growth of tumors, whereas tamoxifen prevents the entry of estrogen into cancer cells. . "Five years of treatment with tamoxifen reduces the risk of breast cancer recurrence by 47% and the risk of death by 26%," wrote Dr. Beat Thurlimann and colleagues. "Despite these benefits, about half the women so treated relapse."

Femara has now been approved by the U.S. Food and Drug Administration fro use in post-menopausal women who have undergone surgery for hormone-sensitive early-stage breast cancer.
'"/>




Page: 1

Related medicine news :

1. New Way to "See" Genes, Evaluate Effectiveness of Gene Therapies Discovered
2. Inhaled Steroids Safe & Effective for Children with Asthma
3. ZD1839 Proves Effective - A Breakthrough in fighting Lung Cancer
4. Fluoride Found Effective in Osteoporosis
5. Aspirin and Warfarin Are Equally Effective for Stroke Prevention
6. Implantable Contact Lens Found Safe and Effective
7. Effective And Economical Agent For Anthrax
8. Stem Cell Transplants May Be Effective For MS Patients
9. Effective therapy for Huntingtons disease
10. Chemotherapy Effective for Bladder Cancer
11. Drug Effective for Vascular Dementia
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/26/2017)... ... April 26, 2017 , ... ... agile ecosystem and domain expertise for sponsors and CROs to speed clinical ... supply management (RTSM) software platform. Bioclinica AGILE RTSM provides seamless ...
(Date:4/25/2017)... ... April 25, 2017 , ... ... Beach, California, committed to raising awareness for Duchenne muscular dystrophy, and funding ... randomized CAP-1002 (cardiosphere-derived cells) Phase I/II HOPE clinical trial in Duchenne announced ...
(Date:4/25/2017)... ... April 25, 2017 , ... Lake Park Dental is now accepting new ... in Lutz, FL. With the help of this highly-effective, yet convenient system, patients ... complications, more discretion and less pain. , Drs. Sarah Jockin, Nicole Morganti, Sara ...
(Date:4/25/2017)... ... April 25, 2017 , ... Buyers and sellers in the thriving ... and head shops –can’t help but be heartened by the industry’s current surge. But ... aptly described as “skunk smell.” At last they can simply, safely and effectively ...
(Date:4/25/2017)... ... 25, 2017 , ... Vetoquinol USA® , a world-class ... part of the EQUISTRO line, at this week’s Rolex Kentucky Three-Day Event in ... immunologic level. , The scientifically-developed Flexadin UCII supports the body’s normal repair of ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... Companion animal vaccines ... pets such as canine, avian and feline. ... such as Attenuated Live Vaccines, Conjugate Vaccines, Inactivated ... Recombinant Vaccines. Attenuated live vaccines are derived from ... have been weakend under laboratory conditions. Conjugate vaccines ...
(Date:4/18/2017)... 2017  Cardinal Health (NYSE: CAH ) ... earnings per share (EPS) guidance and providing a preliminary ... conjunction with this morning,s announcement of the planned acquisition ... Insufficiency businesses. Cardinal Health now believes that ... at the bottom of its previous guidance range of ...
(Date:4/18/2017)... , April 18, 2017  Astute Medical, Inc., developer ... series to be presented at the 2017 National Kidney ... today and continues through April 22. Physicians will present ... used to assess risk for acute kidney injury (AKI) ... failure (ADHF). Elevated levels of TIMP-2 ...
Breaking Medicine Technology: